Enicostemma littorale

Enicostemma littorale Blume

1. Identity, Taxonomy, and Natural Sources

Enicostemma littorale Blume (synonyms: E. hyssopifolium Willd., Enicostemma axillare (Lam.) A. Raynal) belongs to the family Gentianaceae and is a perennial erect herb distributed throughout India up to 450 m in the lower hills. It is now widely recognized that E. littorale is classified as a subspecies of the broader taxon Enicostema axillare, and the two names appear interchangeably across the scientific literature, with "littorale" referring specifically to the subspecies that has been the primary subject of most Indian clinical and pharmacological research.

The plant is a glabrous perennial herb found in open, sandy places among sparse grass, close to beaches throughout the dry zone in Sri Lanka. It is also found in open areas throughout India, Sri Lanka, Malaysia, and tropical Africa, typically at altitudes up to 500 meters. It is a rainy-season herb, growing on moist, damp, and shady ridges and slopes of the borders of cultivated fields, and is widely distributed in India, Eastern and Southern Africa, South America, and Asia.

E. littorale carries a large number of vernacular names reflecting its extensive ethnobotanical footprint. In Sanskrit it is known as Mamajjaka, in English as Indian gentian. Common Hindi names include Chota-Kirayat or Chota-Chirayata. In the Siddha tradition of South India it is called Vellarugu. It is commonly known as the Indian whitehead and has a long history of medicinal use in India and some parts of Africa, including South Africa.

Plant Parts Used

The aerial parts and roots of the plant are used medicinally. The whole plant, leaves, flowers, stem, and roots are mostly used for treatment.

2. Traditional and Historical Use

Ayurveda

The plant found its first mention in the ancient treatise Shodhal Nighantu in the 12th century. Various Ayurvedic texts or Nighantu, such as Shodhal Nighantu and Bhavprakash Nighantu, describe the properties and uses of Mamajjaka, including its antipyretic, anti-helminthic, and Vata disorder treatments.

Mamajjaka holds a significant place in Ayurveda, known for its Pramehaghna (antidiabetic) properties and its ability to balance pitta and kapha doshas. Mamajjaka is noted for its Tikta (bitter) rasa, which is associated with antidiabetic properties, revealing how taste is understood to influence a drug's action and its efficacy in treating specific diseases. More specifically, Mamajjaka has a predominance of Tikta rasa (bitter taste), Ushna virya (hot potency), Katu vipaka (pungent post-digestive effect), and Laghu-Ruksha guna (light and dry quality).

The plant is classified as having beneficial digestive, carminative, stomachic, laxative, and anti-inflammatory effects. It is characterized by its bitter and acrid taste and is known to perform various functions such as aiding liver function, acting as an astringent, and possessing depurative and antiperiodic qualities.

Mamajjaka is one of the herbs used in Madhumeha (diabetic conditions) traditionally in Gujarat, Madhya Pradesh, and Rajasthan. It is widely used in Solapur and Osmanabad districts of Maharashtra in the form of a "leaf pickle" as a dietary supplement for diabetic patients. Acharya Priyavat Sharma described it as useful in madhumeha.

Siddha and Unani Systems

The use of different parts of the medicinal plant in the traditional medicinal systems of Ayurveda, Siddha, and Unani to treat various ailments has been in vogue for several centuries. In the Siddha Medical System, it is used to treat several disease conditions such as diabetes mellitus, rheumatism (Vata diseases), skin diseases (Pitta diseases), constipation, abdominal ulcers, swelling, obesity, and insect poisoning.

Ethnobotanical Uses Across Cultures

The bitter-natured plant acts as a laxative and helps in curing fever, rheumatism, skin diseases, abdominal disorders, snakebite, and obesity, and helps to regulate blood sugar levels. In ancient times, the plant was often used to treat cough, congestion, alleviation of fever, diabetes, and a range of other diseases. The plant parts such as leaves and roots were used in traditional practice for treating several ailments like malaria, skin diseases, leprosy, and diabetes. It has also been used by traditional healers for the treatment of dyspepsia and malaria.

Powdered plant is given with honey as a blood purifier and to help cure dropsy, rheumatism, abdominal ulcers, hernia, swellings, itches, and insect poisoning (Chopra, Nayar and Chopra, 1956).

Traditional Dosage Forms

In Ayurvedic texts, the dose of Mamajjaka is described as 1–3 g of powder, with one formulation being Vayucchaya Surendra taila. In classical Ayurvedic practice, the plant is also processed into a Ghana (a solid aqueous concentrate formed by evaporation of a Kwatha, or decoction). An average yield of 14.78% Ghana is obtained, and physicochemical parameters, qualitative tests for various functional groups, quantitative estimation of total alkaloids, HPTLC profile, heavy metal analysis, and microbial overload have been carried out on Mamajjaka Ghana.

3. Phytochemistry: Key Constituents and Active Compounds

Phytochemical investigations of the species have led to the isolation and identification of numerous chemical constituents, which include alkaloids, saponins, flavonoids, steroids, tannins, proteins, quinines, reducing sugar, coumarins, catechins, sterols, phenolic acids, triterpenoids, xanthones, and swertiamarin.

Secoiridoid Glycosides

Swertiamarin, a secoiridoid glycoside, is considered the major chemotaxonomical marker of the plant responsible for its diverse bioactivities. Swertiamarin, a seco-iridoid glycoside, is mainly found in Enicostemma littorale Blume and exhibits therapeutic activities for various diseases. The molecular weight of swertiamarin is 374, with a molecular formula of C₁₆H₂₂O₁₀. It was isolated and identified on the basis of UV, IR, Mass, and NMR spectroscopic measurements. Another iridoid, gentiopicrin, is also present. A yellow bitter crystalline glycoside called gentiopicrin is present in this plant.

Flavonoids

Monoterpene alkaloids like enicoflavin and gentiocrucine, and seven different flavonoids were isolated from the alcoholic extract: apigenin, genkwanin, isovitexin, swertisin, saponarin, 5-O-glucosylswertisin, and 5-O-glucosylisoswertisin. The presence of catechins, saponins, steroids, sapogenin, triterpenoids, flavonoids, and xanthones, and a new flavone C-glucoside named Verticilliside, was isolated and reported for the first time from this species.

Phenolic Acids

Six phenolic acids were identified: vanillic acid, syringic acid, p-hydroxybenzoic acid, protocatechuic acid, p-coumaric acid, and ferulic acid.

Alkaloids

The presence of monoterpene alkaloids enicoflavin and gentiocrucin has been reported. The plant contains five alkaloids, catechins, saponins, two sterols, triterpenoids, phenolic acids, flavonoids, xanthones, volatile oil, swertiamarin, and gentianine.

Minerals

The plant also contains minerals like iron, potassium, sodium, calcium, magnesium, silica, phosphate, chloride, sulphate, and carbonate.

Other Compounds

At least 60 phytoconstituents have been identified and isolated from E. axillare, including flavonoids, steroids, saponins, triterpenoids, flavonols, phenolics, glycosides, volatile oil, and other compounds. A number of other compounds such as phytosterol, glucoside, sugars, and tannins have been reported.

4. Established and Proposed Mechanisms of Action

Antidiabetic Mechanisms

The plant is reported to enhance glucose-induced insulin release from isolated rat pancreatic islets, mediated through a K⁺-ATP channel-dependent pathway. The mode of action of both swertiamarin and the aqueous extract was found to involve restoring G6Pase and HMG-CoA reductase activities to normal levels, and restoring normal transcriptional levels of PEPCK, GK, Glut 2, PPAR-γ, leptin, adiponectin, LPL, SREBP-1c, and Glut 4 genes, suggesting that both treatments increased insulin sensitivity and regulated carbohydrate and fat metabolism.

An investigation of the glucokinase (GK) activation potential of phytoconstituents of E. littorale through molecular docking showed that, after screening through the Lipinski rule of 5, Veber's rule, and ADMET properties, only apigenin, ferulic acid, genkwanin, p-coumaric acid, protocatechuic acid, syringic acid, and vanillic acid were selected for molecular docking studies. Glucokinase activation is a recognized approach for treating type 2 diabetes mellitus, and these findings are preliminary in silico data only.

Screening of various compounds isolated from E. littorale on NIH3T3 cells for their capacity to stimulate islet differentiation was performed, with morphological changes and characterization by Q-PCR, RT-PCR, immunoblotting, immunocytochemistry, and insulin secretion assay used to verify the newly formed islet-like cell clusters. The compound swertisin, a flavone C-glucoside from E. littorale, was implicated in this islet neogenic property. This remains preclinical evidence.

Antihyperlipidemic Mechanisms

Hepatic HMG-CoA reductase activity was significantly reduced in extract-treated hypercholesterolemic rats. The antilipidemic activity has been attributed to the presence of swertiamarin, a bioactive compound in E. littorale plant extract; swertiamarin has been reported to possess hepatoprotective and lipid-regulating properties, primarily through the modulation of cholesterol metabolism and the enhancement of lipolysis.

Anti-inflammatory Mechanisms

The extract was observed to inhibit serum albumin denaturation in a dose-dependent manner. It was concluded that the methanolic extract possesses antiulcer activity, and the anti-inflammatory activity of the extract may be attributed to its antioxidant potential.

Hepatoprotective Mechanisms

Swertiamarin has been reported to exhibit hepatoprotective and antioxidant activities. Swertiamarin was also reported to exert a protective effect on methylglyoxal-induced damage and a preventive effect on diabetic nephropathy. It demonstrated better antiglycation potential than metformin in protein glycation studies. These findings are from preclinical models.

5. Scientific Evidence by Area of Use

5.1 Antidiabetic / Blood Glucose Regulation

Human / Clinical Evidence

Pills prepared from Enicostemma littorale (Gentianaceae) were administered to 84 patients with type 2 diabetes for three months. Estimation of various biochemical parameters showed that E. littorale reduced blood glucose as well as serum insulin levels and prevented the progression of complications in diabetic patients. Significant improvement in kidney function, lipid profile, and blood pressure was observed, suggesting that E. littorale is an effective herbal antidiabetic.

Clinical trials have shown the safety and antidiabetic activity of Enicostemma littorale in diabetic and prediabetic patients. E. axillare subsp. littorale has undergone some clinical trials with effective outcomes on diabetes. However, the number of published, peer-reviewed clinical trials identified in the literature remains small. The primary published human study involved 84 patients administered pills for three months and lacked a parallel placebo arm, which represents a significant methodological limitation. Overall, the human clinical evidence base is preliminary.

Preclinical / Animal Evidence

The effect of aqueous extract of E. littorale at 2 g/kg orally daily for 6 weeks was studied in neonatal non-insulin-dependent diabetes mellitus (NIDDM) rats. After 3 months of streptozotocin injection, when animals were confirmed as diabetic, E. littorale was administered for 6 weeks. Fasting and fed glucose and insulin levels in NIDDM were significantly (P<0.05) higher than control rats, and they were significantly decreased by treatment with E. littorale.

Swertiamarin (50 mg/kg) and aqueous extract (15 grams dried plant equivalent extract/kg) were administered to rats orally for 40 days and tight regulation of serum glucose, insulin, and lipid profile was found in both groups. These animal doses should not be extrapolated to humans without formal pharmacokinetic bridging studies.

Evidence Strength: For antidiabetic effects, there is one small, uncontrolled human clinical study, multiple animal model studies with consistent glucose-lowering effects, and in vitro mechanistic data. The overall human evidence is currently preliminary and insufficient to establish clinical recommendations without larger, properly controlled trials.

5.2 Antihyperlipidemic / Cardiovascular Lipid Effects

Enicostemma littorale treatment increased HDL levels and decreased serum cholesterol, triglyceride, LDL, VLDL, and LDL/HDL ratio. In addition, treatment with the extract showed a decrease in activities of erythrocyte catalase, superoxide dismutase, and lipid peroxidation levels, with an increase in reduced glutathione levels compared to cholesterol-fed untreated rats. Liver and kidney cholesterol levels and triglyceride levels were also decreased in treated rats. The reference drug used in this study was lovastatin. These are animal model findings only; no independent human lipid trials have been identified.

In the clinical study involving 84 patients with type 2 diabetes, significant improvement in lipid profile was observed alongside blood glucose changes. This human observation is confounded by the simultaneous antidiabetic effects and the absence of lipid-specific endpoints.

Evidence Strength: Antihyperlipidemic activity is supported by animal studies and one co-primary endpoint in the human clinical study. Evidence is preliminary; no dedicated, randomized human lipid trial has been identified.

5.3 Hepatoprotective Activity

The plant has shown good hepatoprotective activity against paracetamol-induced hepatotoxicity in albino rats. Swertiamarin specifically has been investigated in models of D-galactosamine-induced acute liver damage and carbon tetrachloride-induced liver injury in rats. Conventional phytocompounds from E. littorale exhibit hepatoprotective potential but are noted to be hindered by low bioavailability.

Evidence Strength: Hepatoprotective activity is supported by preclinical animal studies. No human clinical trials specifically designed to test hepatoprotection have been identified in the peer-reviewed literature.

5.4 Anti-inflammatory and Antiulcer Activity

The antiulcer and in vitro anti-inflammatory activities of the aerial parts of E. littorale against aspirin, ethanol, and pyloric ligation-induced ulcers in rats and bovine serum albumin denaturation were studied. The extract (200 mg/kg and 400 mg/kg orally) was administered to overnight-fasted rats, one hour prior to aspirin/alcohol/pyloric ligation challenge.

Pre-treatment with the extract showed a dose-dependent decrease in the ulcer index against aspirin, ethanol challenge, and pyloric ligation models. The prior administration of the extract also reduced total acidity, free acidity, and volume of gastric secretion, and elevated the gastric pH.

Evidence Strength: Anti-inflammatory and antiulcer activities are supported by in vitro and animal model studies. No human trials specifically targeting inflammation or gastric ulcers with E. littorale have been identified.

5.5 Antioxidant Activity

Anti-inflammatory, antimalarial, hepatomodulatory, hepatoprotective, antihyperglycemic, hypoglycemic, antioxidant, antitumor, hypolipidemic, and antihelminthic activities of E. littorale have been reported. The antioxidant properties have been evaluated both in vitro and in vivo in animal models, with increases in reduced glutathione and modulation of oxidative enzyme activity documented in cholesterol-fed rats.

Evidence Strength: Antioxidant activity is confirmed in preclinical systems; no specific human antioxidant trial has been published.

5.6 Anticancer / Chemopreventive Activity

The cytotoxic effect of extracts was evaluated in HepG2 (hepatocellular carcinoma) cells. The alcoholic extract exhibited concentration-dependent cytotoxicity, with anticancer activity observed at an IC₅₀ value of 373 ± 3.0 µg/mL in HepG2 cells. On day 21 in a xenograft model, a marked reduction in tumor volume was noted. The findings suggest that the alcoholic extract of E. littorale is effective against hepatocellular carcinoma. However, to fully understand the anticancer potential of E. littorale, further research with specific phytoconstituents is required.

Enicostemma littorale has been recommended in Indian traditional medicines such as Ayurveda for the treatment of various illnesses, including inflammation, diabetes mellitus, and cancer. Experimental studies have also reported its antioxidant, hepatoprotective, and anticancer potential.

Evidence Strength: Anticancer activity is limited to in vitro cell-line studies and animal xenograft experiments. No human clinical oncology data exist. This area must be considered highly preliminary.

5.7 Antimicrobial Activity

Chloroform, methanol, and acetone extracts of different parts of E. littorale (leaf, stem, and root) were evaluated for antimicrobial activity using the disc diffusion method against gram-negative species such as Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Salmonella typhi, and gram-positive species Staphylococcus aureus, Bacillus cereus, and Bacillus subtilis. The chloroform extracts showed the highest antibacterial activity, and among leaf, stem, and root extracts, stem extracts showed maximum antibacterial activity. All of the used extracts had no significant antifungal activity against Aspergillus fumigatus and Aspergillus flavus.

Evidence Strength: Antibacterial activity has been demonstrated in vitro in preliminary studies; antifungal activity was not significant. No in vivo or human antimicrobial data have been identified.

5.8 Antidepressant Activity

One study demonstrated that sodium orthovanadate induces depression in animals and also established the antidepressant activity of E. littorale in an animal model. This is a single preclinical study; no human evidence exists.

Evidence Strength: Extremely preliminary; limited to a single animal model study.

6. Body Systems and Health Areas of Association

• Endocrine / Metabolic System: E. littorale is administered in Ayurvedic pill form for treating type 2 diabetes since it plays a major role in reducing blood glucose, increases serum insulin level, and significantly improves kidney function, lipid profile, systolic and diastolic blood pressure, and pulse rate.
• Hepatic System: Hepatoprotective activity against chemically induced liver injury has been documented in animal models using both the whole extract and isolated swertiamarin.
• Gastrointestinal System: The leaves have varied usages such as antiulcer and anti-nociceptive. Traditional laxative and carminative uses are well documented across Ayurveda, Siddha, and Unani texts.
• Cardiovascular System: Antihyperlipidemic effects in animal models point toward a potential cardiovascular protective role; preliminary human data from the clinical study showed improvement in blood pressure and lipid profiles in diabetic patients.
• Immune / Inflammatory System: Anti-inflammatory activity documented in bovine serum albumin denaturation assays and animal ulcer models.
• Pancreatic / Islet Biology: Apart from antidiabetic activity, an islet neogenic property of swertisin and normoglycemia in a diabetic rat have been reported.
• Nervous System: Antidepressant and antinociceptive activities have been reported in animal models.
• Dermatological: Traditional use for skin diseases, leprosy, and wound healing has been recorded across multiple systems of medicine.

7. Dosage Forms and Reported Dosages

The following dosages appear only as reported in specific studies and traditional texts; they are not recommendations.

• Ayurvedic powder (Churna): 1–3 g of powder, as described in Ayurvedic texts.
• Pills (clinical study, human): Pills prepared from E. littorale were administered to 84 patients with type 2 diabetes for three months. Exact pill dosage in mg was not specified in the retrieved abstract.
• Aqueous extract (animal study): Aqueous extract reduces glucose level and decreases elevated cholesterol, triglyceride, and creatinine levels when administered daily at 2 g/kg orally for 6 weeks in neonatal NIDDM rats.
• Swertiamarin isolated compound (animal study): Swertiamarin at 50 mg/kg and aqueous extract at 15 g dried plant equivalent extract/kg were administered to rats orally for 40 days.
• Antiulcer study (animal): The extract at 200 mg/kg and 400 mg/kg orally was administered to overnight-fasted rats one hour prior to challenge.
• Ghana (Ayurvedic solid decoction): Prepared from a Kwatha (aqueous decoction) and concentrated to a solid form. An average yield of 14.78% Ghana is obtained from the starting plant material.
• Leaf pickle (folk preparation): In the Solapur and Osmanabad districts of Maharashtra, the plant is used in the form of "leaf pickle" as a dietary supplement in diabetic patients.

8. Safety Considerations

General Toxicity Profile

Enicostemma littorale is generally considered of low toxicity, with studies indicating that it does not produce significant toxicity in rats. Swertiamarin, an active component of E. littorale, was studied for acute and subchronic toxicity. Results indicated no significant toxicity or mortality in the animal models, confirming the safety of the drug.

Heavy Metal Content

Enicostemma littorale has very low toxicity and the presence of heavy metals was below the WHO/FDA permissible limits.

Interactions and Co-administration Considerations

The result of a single clinical study with E. littorale showed a significant effect on hypotensive, hypoglycemic, and lipid-lowering drug responses. This is a factual observation from the literature indicating that co-administration with antidiabetic, antihypertensive, or lipid-lowering agents may produce additive pharmacodynamic effects. No specific pharmacokinetic drug interaction data were identified in the sources reviewed.

Bioavailability Limitations

Conventional phytocompounds from E. littorale exhibit hepatoprotective potential but are noted to be hindered by low bioavailability. Research into nanoparticle-based delivery systems (including green-synthesized silver nanoparticles) has been initiated to address this limitation, though this remains at the experimental stage.

Limitations of the Current Evidence Base

The extracts and active constituents of E. axillare have been investigated and reported to demonstrate pharmacological activities in preclinical studies, including antioxidant, anti-inflammatory, anticancer, antidiabetic, antihyperlipidemic, antipyretic, hepatoprotective, and antinociceptive activities. In addition, E. axillare subsp. littorale has undergone some clinical trials with effective outcomes on diabetes. The predominant body of evidence is, however, derived from in vitro cell-line experiments and animal model studies. The single identifiable published human clinical study enrolled 84 patients, ran for three months, and was not described as placebo-controlled or randomized in the retrieved sources. Larger, rigorously controlled randomized clinical trials are needed before the full clinical safety and efficacy of E. littorale can be established in any therapeutic area.

References

• Saranya R et al. Pharmacognosy of Enicostemma littorale: A review. Asian Pac J Trop Biomed. 2013;3(1):79–84. PMC3609395
• Maroo J, Vasu VT, Gupta S. Efficacy of Enicostemma littorale in Type 2 diabetic patients. Phytother Res. 2003;17(10):1200–1202. PubMed PMID 15103671
• Murali B, Upadhyaya UM, Goyal RK. Effect of chronic treatment with Enicostemma littorale in non-insulin-dependent diabetic (NIDDM) rats. J Ethnopharmacol. 2002;81(2):199–204. PubMed PMID 12065151
• Vasu VT, Modi H, Thaikoottathil JV, Gupta S. Hypolipidaemic and antioxidant effect of Enicostemma littorale Blume aqueous extract in cholesterol-fed rats. J Ethnopharmacol. 2005;101(1-3):277–282. PubMed PMID 15955647
• Patel MB et al. Swertiamarin: An Active Lead from Enicostemma littorale Regulates Hepatic and Adipose Tissue Gene Expression by Targeting PPAR-γ and Improves Insulin Sensitivity in Experimental NIDDM Rat Model. Evid Based Complement Alternat Med. 2013;2013:358673. PMC3690633
• Enicostema littorale: a new source of swertiamarin. PubMed PMID 16414773
• Patel N et al. The Molecular Targets of Swertiamarin and its Derivatives Confer Anti-Diabetic and Anti-Hyperlipidemic Effects. Curr Drug Targets. 2018;19(16):1958–1967. PubMed PMID 29623834
• Khan A et al. Investigation of phytoconstituents of Enicostemma littorale as potential glucokinase activators through molecular docking for the treatment of type 2 diabetes mellitus. In Silico Pharmacol. 2021;10(1):1. PubMed PMID 34926125
• Muhamad Fadzil NS et al. Chemistry, Pharmacology and Therapeutic Potential of Swertiamarin – A Promising Natural Lead for New Drug Discovery and Development. Drug Des Devel Ther. 2021;15:2721–2746. PMC8233004
• Preliminary study on the antimicrobial activity of Enicostemma littorale using different solvents. PubMed PMID 22647818
• Roy SP et al. Antiulcer and Anti-inflammatory Activity of Aerial Parts of Enicostemma littorale Blume. J Young Pharm. 2010;2(4):369–373. PMC3019375
• Modulating Effect of Enicostemma littorale on the Expression Pattern of Apoptotic, Cell Proliferative, Inflammatory and Angiogenic Markers During DMBA Induced Hamster Buccal Pouch Carcinogenesis. PMC4721161
• Antidepressant Activity of Enicostemma littorale Blume in Shp2-inhibited Animal Model of Depression. PubMed PMID 27761214
• Ethnomedicinal uses, phytochemistry, pharmacological activities, and toxicology of Enicostema axillare (Lam.) A. Raynal: A review. South African Journal of Botany. 2023.
• Pharmaceutical standardization of Mamajjaka (Enicostemma littorale Auct. non Bl) Ghana. PMC3611629
• Phytochemical analysis and antimicrobial activity of Enicostemma littorale. Journal of King Saud University – Science.
• Kavathiya K et al. An Unexplored Drug Mamajjaka (Enicostemma Littorale Blume) – A Drug Review. AYUSHDHARA.
• Understanding the Pharmacokinetics of Mamajjaka (Enicostemma littorale Blume) as a Dietary Supplement in Diabetes Mellitus. Ayurlog: National Journal of Research in Ayurved Science.
• Silver Nanoparticles Synthesized from Enicostemma littorale Exhibit Gut Tight Junction Restoration and Hepatoprotective Activity via Regulation of the Inflammatory Pathway. Pharmaceutics. 2025.